Taysha Gene Therapies (TSHA) Misses Q1 EPS by 24c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($1.31), $0.24 worse than the analyst estimate of ($1.07).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• Activist investors push Seer, Inc. to disclose go-private timeline